Multivariable Cox models for PFS and OS
| Variable . | Category . | PFS (36 events) . | OS (18 events) . | ||
|---|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | ||
| B symptoms | No B symptoms | Reference | Reference | ||
| B symptoms | 2.56 (1.18, 5.52) | .017 | 2.15 (0.69, 6.67) | .184 | |
| MALT-IPI scores | 0 | Reference | Reference | ||
| 1 | 1.68 (0.54, 5.20) | .371 | 3.91 (0.48, 31.99) | .203 | |
| 2-3 | 1.79 (0.55, 5.81) | .333 | 1.80 (0.19, 16.76) | .607 | |
| Rituximab maintenance | No | Reference | Reference | ||
| Yes | 0.15 (0.03, 0.65) | .012 | 0.17 (0.02, 1.33) | .091 | |
| Clinical response | Complete response | Reference | Reference | ||
| Noncomplete response | 2.00 (0.73, 5.52) | .180 | 0.52 (0.05, 5.01) | .569 | |
| Cycles of bendamustine and rituximab | ≥6 | Not included | Reference | ||
| 4-5 | 2.56 (0.75, 8.79) | .134 | |||
| 1-3 | 2.84 (0.60, 13.39) | .186 | |||
| Variable . | Category . | PFS (36 events) . | OS (18 events) . | ||
|---|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | ||
| B symptoms | No B symptoms | Reference | Reference | ||
| B symptoms | 2.56 (1.18, 5.52) | .017 | 2.15 (0.69, 6.67) | .184 | |
| MALT-IPI scores | 0 | Reference | Reference | ||
| 1 | 1.68 (0.54, 5.20) | .371 | 3.91 (0.48, 31.99) | .203 | |
| 2-3 | 1.79 (0.55, 5.81) | .333 | 1.80 (0.19, 16.76) | .607 | |
| Rituximab maintenance | No | Reference | Reference | ||
| Yes | 0.15 (0.03, 0.65) | .012 | 0.17 (0.02, 1.33) | .091 | |
| Clinical response | Complete response | Reference | Reference | ||
| Noncomplete response | 2.00 (0.73, 5.52) | .180 | 0.52 (0.05, 5.01) | .569 | |
| Cycles of bendamustine and rituximab | ≥6 | Not included | Reference | ||
| 4-5 | 2.56 (0.75, 8.79) | .134 | |||
| 1-3 | 2.84 (0.60, 13.39) | .186 | |||